Every candidate and consultant is evaluated against the actual regulatory and operational context of the role. Our four-step process is built around GxP depth, validation lifecycle experience, and inspection-readiness posture in regulated life sciences environments. For project-based work, we also look for people who can step into your organization's specific situation and contribute from day one.
We screen for regulatory depth in FDA-regulated operations, GxP validated environment experience, documentation quality, and the ability to operate under inspection pressure.
Before sourcing begins, we define the search against validation lifecycle phase, FDA audit exposure, system criticality, and your GxP regulatory posture. That means a structured conversation about where the role sits in your compliance environment and what qualified looks like given your specific validated systems and regulatory standing. A pharmaceutical organization under active FDA scrutiny requires a different candidate profile than a CDMO building a new program. We scope accordingly.
Candidates are evaluated on their applied experience with the regulatory frameworks relevant to your environment: 21 CFR Parts 11, 210/211, and 820; EU Annex 11; GAMP 5; IQ/OQ/PQ; ICH Q10; and change control under GMP. Through structured conversation, we distinguish candidates who have operated these frameworks under production conditions at regulated organizations from those with peripheral exposure. That distinction does not surface on a résumé.
We assess the quality, defensibility, and regulatory rigor of candidates' documentation practices and their direct FDA or notified body audit interaction history. In pharmaceutical and biotech organizations, documentation is evidence that FDA investigators may examine. We explore whether candidates produce audit-defensible records under production pressure and probe their direct inspection interaction, including 483 observation response experience.
You receive a concise shortlist aligned to your search criteria. Every submission includes context on the candidate's regulatory background, production system experience, and documentation approach, and a clear explanation of why they fit your organization and the specific demands of the role.
Hiring for GxP-regulated roles carries compliance risks that surface only through deep, domain-specific evaluation. The process below reflects how we approach every engagement in this practice.
Technical aptitude matters. So does understanding what it means to operate within a change-controlled, inspection-ready system where documentation quality has patient safety consequences.
Organizations under active FDA scrutiny, including warning letters, consent decrees, or pre-approval inspections, operate under fixed remediation timelines with real consequences. We screen with that regulatory urgency in mind.
In pharmaceutical and biotech organizations, documentation is evidence that FDA investigators may examine directly. We assess whether candidates produce audit-defensible records under production conditions, not just during pre-inspection preparation.
A pharma validation lead, a biotech CSV specialist, and a CDMO quality systems manager are different searches. Each is scoped against the specific regulatory environment, production system landscape, and compliance posture of the organization.
FDA-regulated organizations are inspection-ready at all times, not just during active preparation windows. We look for professionals who operate with that posture as a baseline.
In pharmaceutical, biotech, and medical device organizations, validated systems and quality processes ultimately protect patients. We evaluate candidates against that standard, because that is the standard your organization is held to.
Tell us about the role and your GxP environment. We'll apply the same rigor to your search that your organization applies to validated systems.